Contact: director Sandra Giannini
rue de Institut
Website: GSK Bio
6 articles with GSK Bio
Wednesday, the FDA’s VRBPAC agreed that GSK's respiratory syncytial virus vaccine candidate is safe and effective in older adults.
The FDA's Oncologic Drugs Advisory Committee voted 8-5 that two single-arm trials would be “sufficient to characterize the benefits and risks” of Jemperli in locally advanced rectal cancer.
In the heated race for a new respiratory syncytial virus vaccine for older adults, Pfizer gained ground on GSK after winning priority review designation for its vaccine candidate.
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK’s RUBY/ENGOT-EN6/GOG3031/NSGO Phase 3 trial of JEMPERLI.
GSK has pulled out of its partnership focused on developing T-cell receptor therapeutics for solid tumors with Immatics, the German biotech revealed in its Q3 financial results published Thursday.
GSK terminated its cell therapy pact with Lyell Immunopharma. It's opting to advance its own programs without use of Lyell’s T-cell modulating technologies that were at the center of the partnership.